🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "significant breakthrough" in the battle against increasingly resistant strains of the infection, according to researchers.

An International Public Health Issue

The sexually transmitted infection are increasing around the world, with estimates suggesting more than 82 million infections per year. Particularly high rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, escalating drug resistance and the very limited available drugs currently available.”

Health officials are increasingly worried about the surge in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Gain Authorization

One new antibiotic, also known as Nuzolvence, was approved by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Experts believe that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in close succession. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This approval signifies a significant shift in the therapy of superbug gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Outcomes and Worldwide Availability

According to results released by a major medical journal, zoliflodacin cured more than 90% of genital gonorrhoea infections. This establishes an equal footing with the current standard treatment, which involves two antibiotics. The trial involved hundreds of patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to register and commercialise the drug in numerous developing nations.

Doctors treating patients have voiced positive views. Access to a one-pill regimen such as this is hailed as a "revolutionary step" for gonorrhoea control. This is considered crucial to lessen the impact of the infection for patients and to stop the proliferation of untreatable gonorrhoea worldwide.